What Is GHRP-6? Definition and What Research Reports
GHRP-6 (growth hormone-releasing peptide-6) is a synthetic six-amino-acid peptide classified as a growth hormone secretagogue, meaning it was designed to interact with the ghrelin receptor pathway that regulates growth hormone release. It is not an approved medicine in the United States and appears in the literature almost entirely as a laboratory and animal-model compound. Published preclinical papers have reported findings in models of stroke, wound repair, scarring, doxorubicin-induced cardiac damage, acute kidney injury and acute lung injury.
Plain definition
GHRP-6 stands for growth hormone-releasing peptide-6. It is a small, laboratory-made peptide — a chain of six amino acids — that belongs to a family of molecules called growth hormone secretagogues. The name describes what the compound was originally designed to do: interact with a receptor system in the body that helps regulate the pulsed release of growth hormone from the pituitary gland. GHRP-6 is not a hormone itself, and it is not growth hormone; it is a short synthetic peptide studied mainly in cell cultures and animals. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question.
What GHRP-6 is in biochemical terms
Structure and class
GHRP-6 is a hexapeptide — six amino acid residues joined in a chain, with the C-terminus in amide form. It is described in the literature by the shorthand sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The presence of D-form amino acids (mirror-image versions of the natural L-forms) is a common synthetic design feature intended to slow enzymatic breakdown. Because it is synthetic, GHRP-6 has no dietary or endogenous source; it exists only as a manufactured research material.
Receptor class and terminology
GHRP-6 is grouped pharmacologically with ligands of the growth hormone secretagogue receptor (GHS-R1a), the same receptor family that responds to the stomach-derived hormone ghrelin. For this reason GHRP-6 is often called a ghrelin receptor agonist or a ghrelin mimetic in papers, and it is distinct from GHRH analogues, which act on a different receptor. Much of the modern preclinical literature no longer frames GHRP-6 primarily by growth hormone output at all; instead it is discussed as a cytoprotective agent, with endpoints measured as tissue damage rather than hormone levels — for example, in a study of doxorubicin-induced myocardial and extra-myocardial damage where researchers reported activation of prosurvival mechanisms (PMID 38873418) and in a proteome-based study of cutaneous hypertrophic scarring (PMID 29464859).
Regulatory status
GHRP-6 is not an approved drug product in the United States. It has no FDA-approved labelling, no assigned indication, and no standardised human prescribing information. Material sold under the name is typically labelled research-use-only (RUO), which is a supply designation rather than any statement about safety or efficacy in people. GHRP-6 also appears on anti-doping prohibited lists as a growth hormone secretagogue, a status that reflects sport regulation rather than medical evidence.
How the term is used in peptide research
In the published literature, “GHRP-6” is used in three broad ways:
- As a pharmacological tool for probing the ghrelin/GHS-R1a signalling axis in cells and animals.
- As a candidate cytoprotective agent in animal models of organ injury, where outcomes are measured as tissue damage, survival signalling or fibrosis rather than growth hormone concentration — for example in an acute kidney injury model delivered via a hydrogel formulation, where the study framed the mechanism as metabolic regulation (PMID 41327290).
- As a comparator or combination partner, as in experimental stroke work that examined epidermal growth factor together with GHRP-6 (PMID 23314006).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhere the term is misused
- Treating GHRP-6 as growth hormone. It is a secretagogue-class peptide, not a hormone replacement, and the two are not interchangeable terms.
- Confusing it with GHRH analogues. GHRP-6 is frequently lumped in with sermorelin, tesamorelin or CJC-1295, which act through the GHRH receptor. The abbreviations look similar; the receptor targets are not.
- Blurring it with other GHRPs. GHRP-2, hexarelin and ipamorelin are separate molecules with separate literatures. Findings reported for one are not evidence for another.
- Reading animal organ-injury findings as human outcomes. The cited papers describe rodent and laboratory models — for instance acute lung injury and its progression to interstitial fibrosis (PMID 41534456) — and animal findings do not establish what happens in people.
- Assuming mechanism equals benefit. Describing a survival-signalling pathway, as researchers did in a glutamate excitotoxicity model (PMID 17076656), documents biology, not a clinical result.
What the published literature reports
Neurological injury models
A 2006 neurochemistry study examined GHRP-6 in the context of glutamate-induced excitotoxicity and reported that the peptide acted as a survival factor in that model (PMID 17076656). Separately, a 2013 experimental stroke paper investigated epidermal growth factor and GHRP-6 as a combined therapeutic approach, with the study framing the work as restorative neurology in an animal model (PMID 23314006). Neither report described outcomes in human stroke patients.
Skin, wound and scar models
A 2016 paper reported that GHRP-6 enhanced the wound repair process and improved the esthetic outcome of wounds in the model used (PMID 27200188). A 2018 proteome-based study reported early mechanistic data indicating that GHRP-6 prevented cutaneous hypertrophic scarring in its experimental setting (PMID 29464859). Both papers described mechanistic and morphological endpoints rather than growth hormone measurements.
Cardiac, kidney and lung models
A 2024 pharmacology paper reported that GHRP-6 prevented doxorubicin-induced myocardial and extra-myocardial damage by activating prosurvival mechanisms in the model studied (PMID 38873418). A 2025 nanobiotechnology study formulated GHRP-6 into a hydrogel for acute kidney injury and attributed the reported effect to metabolic regulation (PMID 41327290). A 2026 immunopharmacology paper reported that GHRP-6 ameliorated acute lung injury and its subsequent evolution toward interstitial fibrosis in the experimental system described (PMID 41534456).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appAdverse Events: What Studies Report
The verified papers summarised on this page are preclinical investigations of injury models; their published abstracts centred on efficacy-type endpoints such as tissue damage, scar formation, survival signalling and fibrosis rather than on tolerability profiles in people. For example, the acute kidney injury hydrogel study reported mechanism-focused outcomes (PMID 41327290), and the doxorubicin cardiotoxicity study reported protective signalling endpoints (PMID 38873418). Because none of these reports characterised a human adverse-event profile, the literature reviewed here does not support any statement about how GHRP-6 is tolerated by people. Absence of reported harms in animal efficacy studies is not evidence of safety.
Related terms
| Term | How it relates to GHRP-6 |
|---|---|
| Growth hormone secretagogue (GHS) | The broader class GHRP-6 belongs to; describes compounds that act on the GHS-R1a receptor pathway. |
| Ghrelin / GHS-R1a | The endogenous hormone and receptor that define the pathway GHRP-6 is grouped with. |
| GHRP-2, hexarelin, ipamorelin | Other synthetic peptides in the same general class, each with a distinct sequence and separate literature. |
| GHRH analogues (e.g. sermorelin) | A different receptor family; commonly confused with GHRPs because of similar abbreviations. |
| Hexapeptide | Structural descriptor: a peptide of six amino acids, which is what GHRP-6 is. |
| Research-use-only (RUO) | Supply/labelling designation applied to unapproved materials; not a safety or efficacy claim. |
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeHow to read claims about GHRP-6
When evaluating any statement about this peptide, useful questions include: was the finding in cells, animals or humans; what endpoint was actually measured; was GHRP-6 studied alone or in combination, as in the stroke work that paired it with epidermal growth factor (PMID 23314006); and was the delivery method conventional or a specialised formulation such as a hydrogel (PMID 41327290)? These details change what a result can reasonably be said to show. Again, this page is educational only and is not medical advice.
References
- Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation (Journal of Nanobiotechnology, 2025)
- Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms (Frontiers in Pharmacology, 2024)
- Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study (International Wound Journal, 2018)
- Growth hormone releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity (Journal of Neurochemistry, 2006)
- Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds (Plastic Surgery International, 2016)
- Epidermal growth factor and growth hormone-releasing peptide-6: combined therapeutic approach in experimental stroke (Restorative Neurology and Neuroscience, 2013)
- Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis (International Immunopharmacology, 2026)
Frequently asked questions
What does the abbreviation GHRP-6 stand for?▾
GHRP-6 stands for growth hormone-releasing peptide-6. It is a synthetic hexapeptide — six amino acids — grouped pharmacologically with growth hormone secretagogues that interact with the ghrelin receptor pathway. It is not growth hormone itself. Recent preclinical papers often study it for tissue-level endpoints, such as a hydrogel formulation tested in acute kidney injury (PMID 41327290).
Is GHRP-6 an approved medicine?▾
No. GHRP-6 has no FDA-approved product labelling or assigned indication in the United States, and material carrying the name is typically designated research-use-only, a supply label rather than a safety statement. The published work summarised here is preclinical, including animal models of acute lung injury and fibrosis (PMID 41534456) and doxorubicin-induced cardiac damage (PMID 38873418).
How is GHRP-6 different from GHRH analogues like sermorelin?▾
They act through different receptor systems. GHRP-6 is classified with ghrelin receptor (GHS-R1a) ligands, while sermorelin-type compounds are GHRH receptor analogues. The similar abbreviations cause frequent confusion. GHRP-6's own literature is largely organ-injury focused, such as a proteome study of cutaneous hypertrophic scarring (PMID 29464859) and an experimental stroke study (PMID 23314006).
What have researchers reported about GHRP-6 in wound and scar models?▾
A 2016 paper reported that GHRP-6 enhanced the wound repair process and improved the esthetic outcome of wounds in the model used (PMID 27200188). A 2018 proteome-based study reported early mechanistic data indicating prevention of cutaneous hypertrophic scarring in its experimental setting (PMID 29464859). Both were preclinical reports, not human clinical outcomes.
Does GHRP-6 research measure growth hormone levels?▾
Not always. Although the name refers to growth hormone release, much of the modern literature reports tissue-damage, survival-signalling or fibrosis endpoints instead. Examples include a glutamate excitotoxicity study describing GHRP-6 as a survival factor (PMID 17076656) and a cardiac study reporting activation of prosurvival mechanisms against doxorubicin-induced damage (PMID 38873418).
What do studies report about adverse events with GHRP-6?▾
The verified papers reviewed here are preclinical efficacy studies whose abstracts focused on injury and repair endpoints rather than human tolerability, as in the acute kidney injury hydrogel work (PMID 41327290) and the acute lung injury study (PMID 41534456). Because no human adverse-event profile was characterised, the cited literature supports no safety conclusions for people.
Why is GHRP-6 often confused with GHRP-2 or ipamorelin?▾
They share a class label and similar naming, but each is a distinct molecule with its own sequence and its own published evidence base. Findings reported for GHRP-6 — such as effects described in an experimental stroke combination study (PMID 23314006) or a scarring proteome study (PMID 29464859) — cannot be transferred to a different peptide.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.